This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Genetic Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations by Marcelo Nicolas Muscarà
Introduction
Marcelo Nicolas Muscarà is an accomplished inventor based in Campinas, Brazil. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of respiratory conditions. His innovative work has led to the development of a unique patent that addresses critical health issues.
Latest Patents
One of Muscarà's notable patents is titled "Budesonide 21-phosphate salts and pharmaceutical compositions containing the same." This invention relates to salts of budesonide 21-phosphate combined with β2 adrenergic agonists, specifically formoterol. The pharmaceutical compositions developed from this patent are designed for the treatment of respiratory inflammatory pathologies, obstructive pathologies, and allergen-induced airway dysfunctions. Additionally, the patent outlines the process for preparing these salts, showcasing Muscarà's innovative approach to pharmaceutical development.
Career Highlights
Marcelo Muscarà is associated with Genetic S.p.a., a company that focuses on advancing pharmaceutical solutions. His work at Genetic S.p.a. has allowed him to collaborate with other talented professionals in the field, contributing to the development of effective treatments for respiratory ailments.
Collaborations
Muscarà has worked alongside notable colleagues such as Giuseppe Caliendo and Giuseppe Cirino. Their combined expertise has fostered a collaborative environment that enhances the innovation process within the company.
Conclusion
Marcelo Nicolas Muscarà's contributions to pharmaceutical innovation, particularly through his patent on budesonide 21-phosphate salts, highlight his commitment to improving respiratory health. His work continues to impact the field positively, paving the way for future advancements in treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile